
About Vista Pharmaceuticals
Vista Pharmaceuticals is a publicly listed company based in Hyderabad (India) founded in 1992. Manufacturer of OTCs and generic prescription products. Its Indian entity Vista Pharmaceuticals Ltd. reported revenue of βΉ5.72 Cr. Vista Pharmaceuticals offers products and services including Generic Drugs and Research and Development Services. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Vista Pharmaceuticals was founded in 1992 in Hyderabad, India, within the pharmaceuticals sector. Generic prescription and over-the-counter products are produced, including tablets, capsules, and liquids across multiple therapeutic categories. Operations focus on expanding the ANDA portfolio in the USA, developing generics for international markets, and delivering contract manufacturing services to other pharmaceutical firms.
- Headquarters Hyderabad, India
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website vistapharmaceuticals.com
- Social LinkedIn
- Legal Name Vista Pharmaceuticals Ltd.
- Market Cap₹38.35 Cr
VISTAPH · BSE
- Share Price₹6.43
+3.21% today
- Revenue₹5.40 Cr
FY 2025-26 · -46.4% YoY
- EBITDA−₹14.62 Cr
Margin -270.7%
- Net Profit−₹12.06 Cr
FY 2025-26 · -158.8% YoY
Associated legal entities of Vista Pharmaceuticals
Vista Pharmaceuticals operates through Vista Pharmaceuticals Ltd., a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vista Pharmaceuticals Ltd. Listed CIN L24239TG1991PLC012264 | Active | 25 Jan 1991 | Nalgonda, Telangana | ₹5.7 Cr | 24 | 11 | View details |
Products & Services of Vista Pharmaceuticals
Vista Pharmaceuticals offers a comprehensive portfolio of products and services, including Generic Drugs and Research and Development Services.
Generic drugs such as tablets, capsules, and liquids are formulated and distributed for various therapeutic categories.
Research and development activities are conducted for the formulation and registration of pharmaceutical products.
Board of directors of Vista Pharmaceuticals Ltd. (Vista Pharmaceuticals)
Vista Pharmaceuticals Ltd. is the primary company behind Vista Pharmaceuticals. The board of Vista Pharmaceuticals Ltd. currently have 9 directors; the longest-serving is Mallem Hanumantha Rao, appointed in 1993. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mallem Hanumantha Rao DIN 00129311 | Director | 16 Sep 1993 | 33 yrs 2 mo | Vista Pharmaceuticals Ltd. |
| Dhananjaya Alli DIN 00610909 | Whole-time director | 07 Sep 2015 | 11 yrs 2 mo | Vista Pharmaceuticals Ltd. |
| Stanley Prabhakar Reddy DIN 07614532 | Director | 12 Aug 2016 | 10 yrs 3 mo | Vista Pharmaceuticals Ltd. |
| Umesh Virupakah Banakar DIN 08074091 | Director | 24 Feb 2018 | 8 yrs 8 mo | Vista Pharmaceuticals Ltd. |
| Divya Bhavani Chakravarthula DIN 08074187 | Director | 24 Feb 2018 | 8 yrs 8 mo | Vista Pharmaceuticals Ltd. |
| Divakar Reddy Yerrabommanahalli DIN 08574891 | Director | 30 Sep 2019 | 7 yrs 1 mo | Vista Pharmaceuticals Ltd. |
| Umakanth Katta DIN 07438554 | Director | 13 Jul 2020 | 6 yrs 4 mo | Vista Pharmaceuticals Ltd. |
| Pavan Sathvik Gilaka DIN 09733182 | Whole-time director | 14 Oct 2022 | 4 yrs 1 mo | Vista Pharmaceuticals Ltd. |
| Murali Meraga DIN 02537507 | Managing Director | 14 Oct 2022 | 4 yrs 1 mo | Vista Pharmaceuticals Ltd. |
IPO & Listings of Vista Pharmaceuticals
Vista Pharmaceuticals is a publicly listed company on the BSE with ticker symbol VISTAPH in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Jan 2002
- Listed onBSE: 524711
- Listed entityVista Pharmaceuticals Ltd.
- Exchange sectorHealth technology
- ISININE427C01021
- Share price₹6.11 (+0.33% on the day) · 2026-10-14
- Market capitalisation₹37.5 Cr
- EPS (diluted, trailing year)₹-1.87
- Volume (last session)5,855
Financials of Vista Pharmaceuticals
Exchange-reported figures of Vista Pharmaceuticals Ltd., the listed company behind Vista Pharmaceuticals (BSE: VISTAPH).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 5.40 | 10.07 | 10.29 | 1.00 | 0.39 | 1.27 | 22.76 |
| Revenue growth | -46.4% | -2.1% | +929.0% | +156.4% | -69.3% | -94.4% | - |
| EBITDA | (14.62) | (4.03) | (3.55) | (4.32) | (1.28) | (1.73) | (4.80) |
| EBITDA margin | -270.7% | -40.0% | -34.5% | -432.0% | -328.2% | -136.2% | -21.1% |
| Profit before tax | (16.15) | (5.30) | (5.18) | (5.88) | (2.63) | (3.81) | (3.94) |
| Net profit | (12.06) | (4.66) | (4.25) | (5.67) | (0.90) | (2.01) | (3.68) |
| Net profit margin | -223.3% | -46.3% | -41.3% | -567.0% | -230.8% | -158.3% | -16.2% |
| EPS (βΉ) | (1.96) | (0.76) | (0.96) | (1.51) | (0.24) | (0.55) | (1.21) |
| Balance sheet | |||||||
| Total assets | - | 52.95 | 48.52 | 46.73 | 48.08 | 43.63 | 45.16 |
| Net worth | - | 45.42 | 40.46 | 36.71 | 35.45 | 32.85 | 29.64 |
| Total debt | - | 7.40 | 7.96 | 9.96 | 12.55 | 10.71 | 15.47 |
| Cash & bank | - | 0.73 | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 |
| Net working capital | - | 17.55 | 13.93 | 14.44 | 16.04 | 8.01 | 15.22 |
| Cash flow | |||||||
| Cash from operations | - | (6.98) | (4.91) | (1.71) | (0.99) | (6.75) | 0.80 |
| Cash from investing | - | (0.44) | (0.79) | (1.27) | (0.01) | (0.30) | (1.73) |
| Cash from financing | - | 8.06 | 5.59 | 3.11 | 0.94 | 6.96 | 0.28 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.42 | 1.46 | 1.52 | 3.23 | 2.56 | 2.49 |
| Revenue growth (YoY) | -100.0% | -100.0% | -5.5% | -41.4% | -15.6% | - | - | - |
| Other income | 0.04 | 0.03 | 0.09 | 0.19 | 0.00 | 0.24 | 0.12 | 0.01 |
| Total expenses | 0.84 | 7.06 | 5.42 | 4.90 | 2.63 | 4.14 | 4.07 | 3.32 |
| EBITDA | (0.84) | (7.06) | (3.00) | (3.44) | (1.11) | (0.91) | (1.51) | (0.83) |
| EBITDA margin | - | - | -124.0% | -235.6% | -73.0% | -28.2% | -59.0% | -33.3% |
| Depreciation | 0.19 | 0.19 | 0.19 | 0.20 | 0.18 | 0.18 | 0.19 | 0.18 |
| Interest | 0.34 | 0.55 | 0.18 | 0.18 | 0.19 | 0.21 | 0.22 | 0.25 |
| Profit before tax | (1.33) | (7.77) | (3.28) | (3.63) | (1.48) | (1.06) | (1.80) | (1.25) |
| Tax | (0.34) | (1.91) | (0.96) | (1.03) | (0.19) | 0.43 | (0.48) | (0.28) |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.42 | 1.46 | 1.52 | 3.23 | 2.56 | 2.49 |
| Revenue growth (YoY) | -100.0% | -100.0% | -5.5% | -41.4% | -15.6% | - | - | - |
| Other income | 0.04 | 0.03 | 0.09 | 0.19 | 0.00 | 0.24 | 0.12 | 0.01 |
| Total expenses | 0.84 | 7.06 | 5.42 | 4.90 | 2.63 | 4.14 | 4.07 | 3.32 |
| EBITDA | (0.84) | (7.06) | (3.00) | (3.44) | (1.11) | (0.91) | (1.51) | (0.83) |
| EBITDA margin | - | - | -124.0% | -235.6% | -73.0% | -28.2% | -59.0% | -33.3% |
| Depreciation | 0.19 | 0.19 | 0.19 | 0.20 | 0.18 | 0.18 | 0.19 | 0.18 |
| Interest | 0.34 | 0.55 | 0.18 | 0.18 | 0.19 | 0.21 | 0.22 | 0.25 |
| Profit before tax | (1.33) | (7.77) | (3.28) | (3.63) | (1.48) | (1.06) | (1.80) | (1.25) |
| Tax | (0.34) | (1.91) | (0.96) | (1.03) | (0.19) | 0.43 | (0.48) | (0.28) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.40 | 10.07 | 10.29 | 1.00 | 0.39 | 1.27 | 22.76 |
| Revenue growth | -46.4% | -2.1% | +929.0% | +156.4% | -69.3% | -94.4% | - |
| Other income | 0.32 | 0.44 | 0.33 | 0.40 | 0.17 | 0.20 | 3.75 |
| Total expenses | 20.02 | 14.10 | 13.84 | 5.32 | 1.67 | 3.00 | 27.56 |
| Employee cost | 0.00 | 2.00 | 1.79 | 0.51 | 0.57 | 1.15 | 1.31 |
| EBITDA | (14.62) | (4.03) | (3.55) | (4.32) | (1.28) | (1.73) | (4.80) |
| EBITDA margin | -270.7% | -40.0% | -34.5% | -432.0% | -328.2% | -136.2% | -21.1% |
| Depreciation | 0.75 | 0.74 | 0.72 | 0.62 | 0.62 | 0.73 | 1.35 |
| Interest | 1.10 | 0.97 | 1.24 | 1.34 | 0.90 | 1.55 | 1.54 |
| Profit before tax | (16.15) | (5.30) | (5.18) | (5.88) | (2.63) | (3.81) | (3.94) |
| Tax | (4.09) | (0.64) | (0.67) | (0.21) | (1.73) | (1.80) | (0.26) |
| Net profit | (12.06) | (4.66) | (4.25) | (5.67) | (0.90) | (2.01) | (3.68) |
| Net profit margin | -223.3% | -46.3% | -41.3% | -567.0% | -230.8% | -158.3% | -16.2% |
| EPS (βΉ) | (1.96) | (0.76) | (0.96) | (1.51) | (0.24) | (0.55) | (1.21) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 12.31 | 9.43 | 7.51 | 7.36 | 7.36 | 6.07 |
| Reserves & surplus | - | 33.10 | 26.22 | 23.04 | 28.09 | 25.49 | 23.57 |
| Shareholders' funds (net worth) | - | 45.42 | 40.46 | 36.71 | 35.45 | 32.85 | 29.64 |
| Secured loans | - | 7.40 | 7.96 | 9.96 | 12.55 | 11.26 | 15.47 |
| Unsecured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | (0.55) | 0.00 |
| Total debt | - | 7.40 | 7.96 | 9.96 | 12.55 | 10.71 | 15.47 |
| Total liabilities | - | 52.95 | 48.52 | 46.73 | 48.08 | 43.63 | 45.16 |
| Assets | |||||||
| Gross block | - | 27.18 | 27.06 | 26.76 | 25.74 | 25.72 | 25.72 |
| Net block | - | 18.70 | 19.32 | 19.74 | 19.33 | 19.93 | 20.66 |
| Capital work in progress | - | 10.14 | 9.82 | 9.33 | 9.08 | 9.08 | 8.78 |
| Investments | - | 0.05 | 0.02 | 0.02 | 0.03 | 0.04 | 0.02 |
| Inventories | - | 8.22 | 6.79 | 7.68 | 9.33 | 9.68 | 9.68 |
| Sundry debtors | - | 13.54 | 14.28 | 11.25 | 10.46 | 2.17 | 10.28 |
| Cash & bank balances | - | 0.73 | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 |
| Loans & advances | - | 2.41 | 2.23 | 4.62 | 3.70 | 3.25 | 1.00 |
| Total current assets | - | 24.90 | 23.39 | 23.75 | 23.56 | 15.24 | 21.19 |
| Total current liabilities | - | 7.35 | 9.46 | 9.31 | 7.52 | 7.23 | 5.97 |
| Net working capital | - | 17.55 | 13.93 | 14.44 | 16.04 | 8.01 | 15.22 |
| Total assets | - | 52.95 | 48.52 | 46.73 | 48.08 | 43.63 | 45.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 | 0.87 |
| Net cash from operating activities | - | (6.98) | (4.91) | (1.71) | (0.99) | (6.75) | 0.80 |
| Net cash from investing activities | - | (0.44) | (0.79) | (1.27) | (0.01) | (0.30) | (1.73) |
| Net cash from financing activities | - | 8.06 | 5.59 | 3.11 | 0.94 | 6.96 | 0.28 |
| Net change in cash | - | 0.64 | (0.11) | 0.13 | (0.07) | (0.09) | (0.64) |
| Closing cash | - | 0.73 | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -46.4% | -2.1% | +929.0% | +156.4% | -69.3% | -94.4% | - |
| EBITDA growth | -262.8% | -13.5% | +17.8% | -237.5% | +26.0% | +64.0% | - |
| PBT growth | -204.7% | -2.3% | +11.9% | -123.6% | +31.0% | +3.3% | - |
| Net income growth | -158.8% | -9.7% | +25.0% | -530.0% | +55.2% | +45.4% | - |
| Revenue CAGR (3Y) | +75.4% | +195.6% | +100.9% | -64.7% | -76.8% | -64.7% | -2.0% |
| EBITDA CAGR (3Y) | +50.1% | +46.6% | +27.1% | -3.5% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -223.3% | -46.3% | -43.8% | -567.0% | -230.8% | -158.3% | -16.2% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5.2% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -11.3% |
| Debt / equity | - | 0.18 | 0.23 | 0.31 | 0.34 | 0.42 | 0.41 |
| Long-term debt / equity | - | 0.06 | 0.11 | 0.17 | 0.24 | 0.24 | 0.18 |
| Interest cover | -7.16 | -20.34 | -29.04 | -27.13 | -47.37 | -63.01 | -25.04 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.37 | 0.38 | 0.04 | 0.02 | 0.05 | 0.91 |
| Inventory turnover | - | 1.34 | 1.42 | 0.12 | 0.04 | 0.13 | 2.17 |
| Debtors turnover | - | 0.72 | 0.81 | 0.09 | 0.06 | 0.20 | 2.44 |
| EPS (βΉ) | (1.96) | (0.76) | (0.96) | (1.51) | (0.24) | (0.55) | (1.21) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 0.00 | 7.38 | 7.56 | 8.13 | 9.64 | 8.93 | 9.76 |
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Vista Pharmaceuticals (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vista Pharmaceuticals
Complete news archive for Vista Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vista Pharmaceuticals
Vista Pharmaceuticals was founded in 1992.
Vista Pharmaceuticals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
The primary company behind Vista Pharmaceuticals, Vista Pharmaceuticals Ltd., reported revenue of βΉ5.72 Cr for FY 2026, down 46% year on year.
Vista Pharmaceuticals was founded in 1992 in Hyderabad, India, within the pharmaceuticals sector. Generic prescription and over-the-counter products are produced, including tablets, capsules, and liquids across multiple therapeutic categories. Operations focus on expanding the ANDA portfolio in the USA, developing generics for international markets, and delivering contract manufacturing services to other pharmaceutical firms.
Vista Pharmaceuticals offers Generic Drugs and Research and Development Services.
Yes, Vista Pharmaceuticals is publicly traded on BSE under the ticker symbol VISTAPH.
Vista Pharmaceuticals operates through Vista Pharmaceuticals Ltd..
The legal entities of Vista Pharmaceuticals currently have 11 directors, including Umakanth Katta, Suneel Pachipala, Pavan Sathvik Gilaka and others.
